PT - JOURNAL ARTICLE AU - Rita Reik AU - Richard R. Gammon AU - Nancy Carol AU - Judith Smith AU - Martin Grable AU - Susan Forbes AU - Yanyun Wu AU - Lance Reed AU - Michael Rogers AU - Alicia Prichard AU - Scott Paul AU - George Scholl TI - Rapid Development of a <em>De Novo</em> Convalescent Plasma Program in Response to a Global Pandemic: A Large Southeastern U.S. Blood Center’s Experience AID - 10.1101/2020.10.23.20217901 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.23.20217901 4099 - http://medrxiv.org/content/early/2020/10/27/2020.10.23.20217901.short 4100 - http://medrxiv.org/content/early/2020/10/27/2020.10.23.20217901.full AB - Background With no vaccine or treatment for SARS-CoV-2 and its associated disease, COVID-19, convalescent plasma from recovered COVID-19 (CCP) patients offered a potential therapy. In March of 2020, the United States (US) Food and Drug Administration (FDA) authorized CCP under emergency Investigational New Drug (eIND) exemption and an IRB-approved Expanded Access Program (EAP) to treat severe COVID-19. Hospital demand grew rapidly in the Southeastern US, resulting in backlogs of CCP orders. We describe a large US blood center’s (BC) rapid implementation of a CCP program in response to community needs.Study Design and Methods From April 2 to May 17, 2020 CCP was collected by whole blood or apheresis. Initial manual approaches to donor intake, collection and distribution were rapidly replaced with automated processes. All CCP donors and products underwent FDA-required screening and testing.Results 619 CCP donors (299 females, 320 males) presented for CCP donation [161 (25.6%) whole blood, 466 (74.1%) plasmapheresis] resulting in 1219 CCP units. Production of CCP increased as processes were automated and streamlined, from a mean of 11 donors collected/day for the first month to a mean of 25 donors collected/day in the subsequent two weeks. Backlogged orders were cleared, and inventory began to accumulate 4 weeks after project initiation.Conclusion The BC was able to implement an effective de novo CCP collection program within 6 weeks in response to a community need in a global pandemic. Documentation of the experience may inform preparedness for future pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board approval was obtained for all donors who participated(Advarra- Pro00038077)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no data available outside of this submitted manuscript.